Core Viewpoint - The stock of Heptagon Pharmaceuticals (02142) rose over 5%, currently up 5.46% at HKD 13.94, with a trading volume of HKD 17.1969 million, following the announcement of a strategic partnership with Evinova at the 8th China International Import Expo to enhance the efficiency of innovative biotherapy development through AI and digital technologies [1] Group 1 - Heptagon Pharmaceuticals and Evinova will leverage their respective strengths to build an AI-driven open ecosystem for drug development [1] - The company recently launched its first fully human AIHCAb model driven by the Hu-mAtrIx AI platform during a global R&D day event in Shanghai [1] - The AIHCAb model is based on proprietary HarbourMice platform data and integrates a fine-tuned large language model (LLM) for sequence generation, complemented by high-precision AI classification and drugability prediction models [1] Group 2 - The platform differs from traditional screening methods by achieving a closed-loop process of AI design, intelligent screening, and wet lab validation [1]
和铂医药-B涨超5% 与Evinova达成战略合作 构建AI驱动药物研发开放式生态系统